# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-049828
Filing Date
2021-04-13
Accepted
2021-04-13 17:25:57
Documents
6
Period of Report
2021-05-25

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm212414-1_def14a.htm | DEF 14A | 1484845
2 | GRAPHIC | lg_nateracondelthrive-4c.jpg | GRAPHIC | 55744
3 | GRAPHIC | sg_stevenchapman-bw.jpg | GRAPHIC | 21628
4 | GRAPHIC | tm212414d1-pc_backbw.jpg | GRAPHIC | 416116
5 | GRAPHIC | tm212414d1-pc_ceoneo4c.jpg | GRAPHIC | 110513
6 | GRAPHIC | tm212414d1-pc_frontbw.jpg | GRAPHIC | 508769
| Complete submission text file | 0001104659-21-049828.txt |  | 3017968

Mailing Address 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753
Business Address 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 650-249-9090
Natera, Inc. (Filer) CIK: 0001604821 (see all company filings)

EIN.: 010894487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37478 | Film No.: 21823787
SIC: 8071 Services-Medical Laboratories